Pharmaceuticals

Vividion Therapeutics to Expand with New Global Research and Development Center

United States of America

  • New facility in San Diego will support continued development of Vividion’s global discovery and clinical portfolio and pave the way for future programs aimed at bringing first-in-class therapeutics to patients in need

  • Chemoproteomics screening capacity will increase by 50 percent to enable Vividion to pursue an expansive range of previously undrugged disease targets

SAN DIEGO – July 23, 2024 – Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.

 

The new facility will support the continued development of Vividion’s R&D capabilities, including a significant increase in the company’s chemoproteomics screening capacity. More than half of the expansion will be dedicated to state-of-the-art research labs where Vividion will continue advancing its expansive portfolio of clinical and preclinical programs as well as future programs that emerge from the company’s discovery efforts. The new facility will accommodate strategic growth capabilities and enable the company to continue to attract and retain top life sciences experts in San Diego, a rapidly growing hub for biotech innovation.  

Vividion has entered an exciting new stage in the company’s development, with multiple programs in clinical trials, a rich discovery portfolio and expansive platform screening efforts focused on bringing more previously undrugged disease-causing targets within the reach of small molecule therapeutics. Our new R&D center and headquarters will provide the infrastructure to execute our strategic vision and continue to lead the way in applying chemoproteomics and covalent chemistry to create first-in-class medicines for patients in need. Vividion’s culture of innovation has always been driven by outstanding people working collaboratively in a dynamic and supportive environment. We’re looking forward to continuing and building on that tradition in our new state-of-the-art home.
Aleksandra Rizo, M.D., Ph.D.
,
Chief Executive Officer of Vividion

“Vividion is a key component of Bayer’s innovation strategy and its focus on bringing first-in-class medicines to market to address longstanding unmet medical needs,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals at Bayer. “This new facility will support our strategic growth opportunities to enable the company to capitalize on the rich array of drug discovery and clinical development opportunities afforded by its pioneering chemoproteomics platform."

 

Bayer has a long-standing track record of delivering scientific innovation for patients. Rebuilding the portfolio, enhancing R&D capabilities, and an ongoing reallocation of resources – including commitment to building on its strong presence in the United States – are key parts of the company’s strategy to achieve sustainable long-term growth. San Diego’s world-renowned biotech cluster is home to hundreds of life science companies and leading research institutes that have made significant contributions to advancements in healthcare. Such an ecosystem holds great promise for Bayer to strengthen its leadership and innovation pipeline. In addition to San Diego, Bayer has successfully developed a local presence in each of the United States’ most innovative life science markets, including Boston, San Francisco and Research Triangle Park - North Carolina.

 


About Vividion
Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.

 

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

 

Find more information about Vividion at www.vividion.com
Find more information about Bayer at https://pharma.bayer.com/
Follow Bayer on Facebook: http://www.facebook.com/bayer

 

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Vividion Media Contact:
Laurie Sherman, phone +1 858.630.8246  
Email: media@vividion.com

 

Bayer Media Contact:
Lisa Hennig, phone +49 172 8693420
Email: lisa.hennig@bayer.com

 

Bayer U.S. Media Contact:
Elaine Colon, phone +1 (732) 2361587
Email: elaine.colon@bayer.com